Skip to content
NewsBlazeIN – Lifestyle
Author:
Lynk Pharmaceuticals Co., Ltd.
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment’s Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
June 1, 2026